PT 17

Drug Profile

PT 17

Latest Information Update: 23 Mar 2007

Price : $50

At a glance

  • Originator Palatin Technologies
  • Class Anti-inflammatories; Anti-ischaemics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Inflammation; Ischaemia

Most Recent Events

  • 29 Jan 2002 Preclinical development for Ischaemia in USA (Unknown route)
  • 29 Jan 2002 Preclinical development for Inflammation in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top